◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › M › MNKD

MannKind Corp (MNKD) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-16

MannKind Corp (MNKD) operates in the BIOTECHNOLOGY industry and is headquartered in Danbury, United States with about 591 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, MNKD reported $349M in revenue and $6M in net income.

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.

Interactive charts & full statements → Open the MNKD valuation workbench →

MNKD Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$394M	$349M	$286M	$199M	$100M	$75M	$65M	$63M	$28M	$12M	$175M	$0M	$0M	$3M	$0M	$0M	$0M	—	$0M	$0M	$0M
Gross Profit	$298M	$288M	$209M	$136M	$42M	$37M	$41M	$35M	$7M	($5M)	$125M	($140M)	$0M	$0M	$0M	$0M	$0M	—	$0M	$0M	$0M
Gross Margin %	75.7%	82.5%	73.2%	68.5%	42.4%	48.5%	62.2%	55.6%	26.5%	-46.7%	71.3%	—	—	0.0%	100.0%	100.0%	100.0%	—	100.0%	100.0%	100.0%
Operating Income (EBIT)	$8M	$39M	$73M	$9M	($64M)	($47M)	($48M)	($45M)	($77M)	($108M)	$67M	($345M)	($180M)	($169M)	($147M)	($141M)	($152M)	($210M)	($306M)	($307M)	($234M)
Operating Margin %	2.0%	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.6%	-70.8%	-274.9%	-921.1%	38.5%	—	—	-5350.6%	-419885.7%	-281078.0%	-163976.3%	—	-1528825.0%	-3073570.0%	-233697.0%
Net Income	($44M)	$6M	$28M	($12M)	($87M)	($81M)	($57M)	($52M)	($87M)	($117M)	$126M	($368M)	($198M)	($191M)	($169M)	($161M)	($171M)	($220M)	($303M)	($293M)	($231M)
Net Margin %	-11.1%	1.7%	9.7%	-6.0%	-87.6%	-107.3%	-87.9%	-82.3%	-312.2%	-999.0%	71.9%	—	—	-6048.3%	-483902.9%	-321608.0%	-183397.9%	—	-1515195.0%	-2931900.0%	-230548.0%
EBITDA	$31M	$28M	$77M	$15M	($56M)	($61M)	($45M)	($39M)	($76M)	($102M)	$65M	($345M)	($160M)	($156M)	($134M)	($124M)	($136M)	($191M)	($288M)	($281M)	($225M)
Earnings Per Share (EPS)	$-0.14	$0.02	$0.10	$-0.04	$-0.34	$-0.32	$-0.26	$-0.27	$-0.60	$-1.13	$1.36	$-4.54	$-2.57	$-3.20	$-4.68	$-6.60	$-7.50	$-10.33	$-14.92	$-18.32	$-22.62
Shares Outstanding (M)	309M	314M	284M	267M	257M	249M	223M	196M	144M	104M	92M	81M	77M	60M	36M	24M	23M	21M	20M	16M	10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MNKD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$109M	$90M	$112M	$82M	$77M	$78M	$77M	$70M
Gross Profit	$80M	$68M	$88M	$62M	$56M	$61M	$57M	$52M
Gross Margin %	73.0%	75.8%	78.5%	75.4%	73.1%	77.6%	74.5%	74.3%
Operating Income (EBIT)	$0M	($3M)	($8M)	$19M	$5M	$22M	$26M	$13M
Operating Margin %	-0.3%	-3.3%	-6.9%	22.9%	6.9%	28.4%	34.5%	18.2%
Net Income	($19M)	($17M)	($16M)	$8M	$1M	$13M	$7M	$12M
Net Margin %	-17.4%	-18.4%	-14.2%	9.7%	0.9%	16.8%	9.7%	16.5%
EBITDA	$13M	$2M	($3M)	$18M	$10M	$27M	$19M	$24M
Earnings Per Share (EPS)	$-0.06	$-0.05	$-0.05	$0.03	$0.00	$0.04	$0.03	$0.04
Shares Outstanding (M)	309M	308M	314M	312M	311M	321M	291M	285M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MNKD Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($8M)	$18M	$43M	$34M	($81M)	($62M)	($28M)	($88M)	($38M)	($65M)	($78M)	($57M)	$4M	($129M)	($120M)	($124M)	($149M)	($184M)	($271M)	($245M)	($190M)
Capital Expenditures (CapEx)	$10M	$5M	$10M	$42M	$8M	$11M	$5M	$3M	$0M	$1M	$1M	$10M	$24M	$8M	$1M	$7M	$10M	$19M	$82M	$78M	$21M
Free Cash Flow (FCF)	($19M)	$14M	$33M	($8M)	($88M)	($73M)	($33M)	($91M)	($38M)	($66M)	($79M)	($68M)	($20M)	($137M)	($120M)	($131M)	($158M)	($203M)	($354M)	($323M)	($211M)
FCF Margin %	-4.7%	3.9%	11.5%	-4.2%	-88.5%	-97.0%	-50.5%	-144.4%	-136.7%	-561.3%	-45.3%	—	—	-4318.4%	-344277.1%	-261390.0%	-170103.2%	—	-1768705.0%	-3234080.0%	-210567.0%
Dividends Paid	—	—	—	—	—	$0M	$15M	$1M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MNKD Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($18M)	($6M)	($8M)	$23M	$9M	($6M)	$23M	$9M
Capital Expenditures (CapEx)	$5M	$2M	$2M	$1M	$1M	$0M	$3M	$1M
Free Cash Flow (FCF)	($23M)	($8M)	($10M)	$22M	$8M	($7M)	$20M	$8M
FCF Margin %	-21.4%	-8.3%	-8.9%	27.2%	10.2%	-8.6%	25.7%	11.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MNKD Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$732M	$792M	$394M	$475M	$295M	$321M	$109M	$94M	$108M	$85M	$107M	$126M	$394M	$259M	$251M	$200M	$277M	$247M	$282M	$543M	$540M
Cash & Cash Equivalents	$53M	$75M	$46M	$238M	$70M	$124M	$67M	$30M	$71M	$44M	$23M	$59M	$121M	$71M	$62M	$3M	$66M	$30M	$28M	$368M	$320M
Total Liabilities	$800M	$843M	$473M	$721M	$546M	$531M	$289M	$284M	$283M	$299M	$291M	$477M	$468M	$289M	$362M	$513M	$463M	$307M	$196M	$179M	$156M
Total Debt (Short + Long-Term)	$321M	$368M	$49M	$269M	$378M	$231M	$9M	$10M	$102M	$157M	$148M	$102M	$222M	$201M	$212M	$211M	$445M	$278M	$142M	$112M	$111M
Total Shareholders' Equity	($67M)	($51M)	($79M)	($246M)	($251M)	($209M)	($180M)	($191M)	($175M)	($215M)	($184M)	($350M)	($74M)	($31M)	($111M)	($314M)	($186M)	($59M)	$87M	$364M	$383M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MNKD viewer.

Other Companies in BIOTECHNOLOGY

APMD · Apnimed, Inc. Common Stock — $1 billion
ANRO · Alto Neuroscience, Inc. — $1 billion
ODTX · Odyssey Therapeutics, Inc. Common Stock — $1 billion
SPTX · Seaport Therapeutics, Inc. Common Stock — $1 billion
SVRA · Savara Inc — $1 billion
OBX · Obsidian Therapeutics, Inc. Common Stock — $1 billion
JBIO · Jade Biosciences, Inc. — $1 billion
MLTX · MoonLake Immunotherapeutics — $1 billion

← MNIN All “M” companies MNKS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.